Sage Therapeutics has sued Biogen in Delaware court, one week after receiving a $469 million buyout offer from the larger ...

Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the ...

J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference.

Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...

Wall Street stocks were mixed after a choppy session as traders digested better-than-expected inflation data and looked ahead to bank earnings.

Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional ...

Health-care companies rose amid deal activity. Shares of mental-illness drug developer Intra-Cellular rallied after health-care conglomerate Johnson & Johnson agreed to buy it for $15 billion, ...

Biogen proposes acquiring Sage Therapeutics for $7.22 per share, as analysts highlight the strategic value of Zurzuvae's ...

J&J agreed to buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of reentry into neuroscience by large ...

Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...

Biogen is looking to augment growth by hunting for biotechs with drugs in mid- and late-stage clinical development.